The relationship between schizophrenia polygenic scores, blood-based proteins and psychosis diagnosis in the UK Biobank
Open Access
- 14 January 2026
- journal article
- research article
- Published by Springer Nature in Schizophrenia
- Vol. 12 (1)
Abstract
Despite notable progress in psychiatric genomics, there are no validated blood-based biomarkers for psychosis. Previous studies have failed to establish a link between schizophrenia polygenic scores (PGS) and blood protein levels. We aimed to identify associations between schizophrenia PGS and blood-based proteins, and to determine whether levels of 2077 proteins differ in individuals with psychosis. We analysed proteomic and genomic data from 47,969 participants in the UK Biobank. Association analyses in the 47,678 participants without psychosis (mean age 57.1 years, standard deviation 8.1 years; 54% female) identified nominal associations ( p < 0.05) of schizophrenia PGS with 102 proteins. Four of these (TMPRSS15, ADGRB3, CEACAM21, and KLK1) met the false discovery rate (FDR) threshold of < 0.05. We investigated the association of these four proteins with psychosis in a matched case-control sample (283 cases, 849 controls, mean age 56.9 years, standard deviation 8.4 years; 48% female). In individuals with psychosis, we observed significantly lower levels of KLK1, even after adjusting for potential confounders (effect size −0.25, SE 0.09, FDR 0.049). This direction of effect was opposite to that observed in the primary analysis of individuals without psychosis (effect size 324.67, SE 48.32, FDR 3.85 × 10 −8 ). The effect of antipsychotic medication did not explain this difference. This protein should be taken forward for further study and validation to investigate its potential as a psychosis biomarker.Keywords
Funding Information
- NIHR Mental Health Translational Research Collaboration Mission
- RCUK | Medical Research Council (MR/Z503745/1)
- RCUK | Medical Research Council (MR/Y004094/1)
- RCUK | Medical Research Council (MR/Y004094/1)
This publication has 53 references indexed in Scilit:
- The Role of SLC39A8 .p.( Ala391Thr ) in Schizophrenia Symptom Severity and Cognitive Ability: Cross‐Sectional Studies of Schizophrenia and the General UK PopulationAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2025
- Genetic and Phenotypic Features of Schizophrenia in the UK BiobankJAMA Psychiatry, 2024
- Associations between major psychiatric disorder polygenic risk scores and blood-based markers in UK biobankBrain, Behavior, and Immunity, 2021
- Association of Genetic Liability to Psychotic Experiences With Neuropsychotic Disorders and TraitsJAMA Psychiatry, 2019
- Cognitive Performance Among Carriers of Pathogenic Copy Number Variants: Analysis of 152,000 UK Biobank SubjectsBiological Psychiatry, 2017
- Serine proteases, serine protease inhibitors, and protease-activated receptors: Roles in synaptic function and behaviorBrain Research, 2011
- Trypsin and trypsin-like proteases in the brain: Proteolysis and cellular functionsCellular and Molecular Life Sciences, 2007
- Addiction molecular genetics: 639,401 SNP whole genome association identifies many “cell adhesion” genesAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2006
- Schizophrenia as a Complex TraitArchives of General Psychiatry, 2003
- Crystal structure of enteropeptidase light chain complexed with an analog of the trypsinogen activation peptide 1 1Edited by R. HuberJournal of Molecular Biology, 1999